Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 243Stomach Neoplasms 23Breast Neoplasms, Male 16Neoplasm Metastasis 14Neoplasms 8Inflammatory Breast Neoplasms 8Esophageal Neoplasms 8Brain Neoplasms 8Colorectal Neoplasms 6Adenocarcinoma Of Esophagus 4Urologic Neoplasms 3Triple Negative Breast Neoplasms 3HER2-positive Breast Cancer 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Ductal, Breast 3Gallbladder Neoplasms 2Endometrial Neoplasms 2Cholangiocarcinoma 2Carcinoma, Lobular 2Carcinoma, Intraductal, Noninfiltrating 2Biliary Tract Neoplasms 2Adenocarcinoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Solid Cancers 1Rectal Neoplasms 1Prostatic Neoplasms 1Patient Preference 1Patient Compliance 1

Interventions

seribantumab 2zenocutuzumab 1exemestane 1Vinorelbine 1Trastuzumab 1Letrozole 1Fulvestrant 1Erlotinib Hydrochloride 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lethal Congenital Contracture Syndrome 2 × Trastuzumab × Clear all
NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Merus B.V.

Phase 2 Completed
105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡